WO2013053739A1 - Procédé de préparation d'inhibiteurs du facteur xa - Google Patents

Procédé de préparation d'inhibiteurs du facteur xa Download PDF

Info

Publication number
WO2013053739A1
WO2013053739A1 PCT/EP2012/070034 EP2012070034W WO2013053739A1 WO 2013053739 A1 WO2013053739 A1 WO 2013053739A1 EP 2012070034 W EP2012070034 W EP 2012070034W WO 2013053739 A1 WO2013053739 A1 WO 2013053739A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
oxo
phenyl
morpholin
aminomethyl
Prior art date
Application number
PCT/EP2012/070034
Other languages
English (en)
Inventor
Ravindranath Vishnu Newadkar
Avinash Changdeo Gaikwad
Ajay Madhukar Harad
Pere Dalmases Barjoan
Original Assignee
Laboratorios Lesvi, S. L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Lesvi, S. L. filed Critical Laboratorios Lesvi, S. L.
Publication of WO2013053739A1 publication Critical patent/WO2013053739A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • the present invention refers to a process for obtaining rivaroxaban, as well as the preparation of new acid addition salts of 4- ⁇ 4-[(5S)-5-(aminomethyl)-2-oxo-1 ,3- oxazolidin-3-yl]phenyl ⁇ morpholin-3-one useful for the manufacturing of rivaroxaban and pharmaceutical acceptable salts thereof.
  • Rivaroxaban is an orally-active Factor Xa inhibitor, developed by Bayer for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its chemical name is 5-Chloro-N-( ⁇ (5S)-2-oxo-3-[4- (3-oxomorpholin-4-yl)phenyl]-1 ,3-oxazolidin-5-yl ⁇ methyl)thiophene-2-carboxamide having the following structure:
  • Rivaroxaban Rivaroxaban was first disclosed by US patent number US 7,157,456 in which rivaroxaban is prepared by reacting 2-[(2S)-2-oxiranylmethyl]-1 H-isoindole-1 ,3(2H)- dione with 4-(4-aminophenyl)-3-morpholinone to obtain 2-((2R)-2-hydroxy-3- ⁇ [4-(3- oxo-4-morpholinyl)phenyl]amino ⁇ propyl-1 H-isoindole-1 , 3(2H)-dione (I), as depicted in Scheme 1.
  • the present invention provides a process for manufacturing rivaroxaban with a high purity and good yield, which comprises the use of new acid addition salts of following general formula III:
  • HA is an organic acid
  • the process comprising the use of said above organic acid addition salt results is a straightforward reproducible process, which is more environmentally friendly and applicable at industrial scale.
  • the rivaroxaban obtained by the process as herein disclosed has a high purity. Additional advantages of the process as herein disclosed are cycle time, chemical cost, personnel efficiency, reduction in equipment purchases and manufacturing capacity.
  • a process for the manufacturing of rivaroxaban or a pharmaceutically acceptable salt thereof comprises at least the following steps: i) obtaining an acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one, wherein the acid used to form the acid addition salt is an organic acid; ii) reacting the acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one obtained in step (i) with the suitable reagents to obtain rivaroxaban or a salt thereof.
  • an acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one is provided, wherein the acid used to form the acid addition salt is an organic acid.
  • a process for the manufacturing of a novel acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3- yl]phenyl ⁇ morpholin-3-one wherein the acid used to form the acid addition salt is an organic acid.
  • the use of the acid addition salt of the second aspect, for the preparation of rivaroxaban and pharmaceutically acceptable salts thereof and for the preparation of a pharmaceutical composition comprising rivaroxaban or a pharmaceutically acceptable salt thereof is provided.
  • a pharmaceutical composition comprising a therapeutically effective amount of rivaroxaban prepared according to the first aspect together with appropriate amount of pharmaceutically acceptable excipients or carriers is provided.
  • Figure 1 shows powder X-ray diffractogram for the 4- ⁇ 4-[(5S)-5-(amino methyl)-2-oxo- 1 ,3-oxazolidine-3-yl]phenyl ⁇ morpholin-3-one oxalate, obtained by way of Example 6.
  • Figure 2 shows IR spectra of the 4- ⁇ 4-[(5S)-5-(amino methyl)-2-oxo-1 ,3-oxazolidine-3- yl]phenyl ⁇ morpholin-3-one oxalate, obtained by way of Example 6.
  • Figure 3 shows the DSC analysis of the 4- ⁇ 4-[(5S)-5-(amino methyl)-2-oxo-1 ,3- oxazolidine-3-yl]phenyl ⁇ morpholin-3-one oxalate, obtained by way of Example 6.
  • Figure 4 shows the TGA analysis of the 4- ⁇ 4-[(5S)-5-(amino methyl)-2-oxo-1 ,3- oxazolidine-3-yl]phenyl ⁇ morpholin-3-one oxalate, obtained by way of Example 6.
  • Figure 5 shows powder X-ray diffractogram for the 4- ⁇ 4-[(5S)-5-(amino methyl)-2-oxo- 1 ,3-oxazolidine-3-yl]phenyl ⁇ morpholin-3-one malonate, obtained by way of Example 7.
  • Figure 6 shows IR spectra of the 4- ⁇ 4-[(5S)-5-(amino methyl)-2-oxo-1 ,3-oxazolidine-3- yl]phenyl ⁇ morpholin-3-one malonate, obtained by way of Example 7.
  • organic acid refers to organic compounds which comprises one or more carbon-containing radicals and presents acidic properties.
  • the most common organic acids are the carboxylic acids, whose acidity is associated with their carboxyl group -COOH.
  • organic acid also refers as HA contemplates monoprotic, diprotic or triprotic organic acids.
  • a preferred organic acids are R 2 COOH compounds, or to mixtures of R 2 COOH compounds, wherein R 2 is a linear or branched, saturated or unsaturated alkyl, an aryl or a heteroaryl, said R 2 group being optionally substituted by one or more halogen, hydroxyl, alkoxyl, carboxyl, carboalkoxyl, aryl or heteraryl groups, and said acid R 2 COOH having between 1 and 18 carbon atoms.
  • Non-limiting examples of these acids include commercially available oxalic acid, oxalic acid dihydrate, malonic acid, fumaric acid, citric acid, including citric acid monohydrate, maleic acid, tartaric acid, acetic acid, formic acid, trifluoroacetic acid, gluconic acid, lactic acid, malic acid, succinic acid, acetyl salicylic acid, adipic acid, pivalic acid, benzoic acid, phenylacetic acid, p-methoxybenzoic acid, 4-pyridylcarboxylic acid, oleic acid, organosulfur compounds, embonic acid, gentisic acid, glucuronic acid, pyroglutamic acid, glycolic acid, mandelic acid, aspartic acid, hippuric acid, glutaric acid, pimelic acid, palmitic acid and their mixtures.
  • examples of these acids include commercially available organic acids, with the proviso that the organic acid is not oxalic acid, fumaric acid, citric acid, maleic acid, tartaric acid, succinic acid, mandelic acid or benzoic acid.
  • examples of these acids include commercially available oxalic acid dihydrate, malonic acid, citric acid monohydrate, acetic acid, formic acid, trifluoroacetic acid, gluconic acid, lactic acid, malic acid, acetyl salicylic acid, adipic acid, pivalic acid, phenylacetic acid, p-methoxybenzoic acid, 4-pyridylcarboxylic acid, oleic acid, organosulfur compounds, embonic acid, gentisic acid, glucuronic acid, pyroglutamic acid, glycolic acid, aspartic acid, hippuric acid, glutaric acid, pimelic acid, palmitic acid and their mixtures.
  • the term "consisting essentially of refers that the entity or process may comprises further features, but those features do not materially any surprising technical affect.
  • organic solvent refers to an organic molecule capable of at least partially dissolving another substance (i.e., the solute).
  • Organic solvents may be liquids at room temperature.
  • examples of organic solvents that may be used for the present invention include, but are not limited to: hydrocarbon solvents (e.g., n- pentane, n-hexane, n-heptane, n-octane, paraffin, cyclohexane, methylcyclohexane, decahydronaphthalene, mineral oil, crude oils, etc.) which also includes aromatic hydrocarbon solvents (e.g., benzene, toluene, o-xylene, m-xylene, and p-xylene), halogenated hydrocarbon solvents (e.g., carbon tetrachloride, 1 ,2-dichloroethane, dichloromethane, chloroform, etc.), ester solvents (e.g.
  • the organic solvent may be formed by the combination of two or more organic solvents.
  • polar solvent as used herein means a solvent that tends to interact with other compounds or itself through acid-base interactions, hydrogen bonding, dipole- dipole interactions, or by dipole-induced dipole interactions.
  • non-polar solvent as used herein means a solvent that is not a polar solvent. Non-polar solvents interact with other compounds or themselves predominantly through dispersion forces. Non-polar solvents interact with polar solvents mainly through dipole-induced dipole interactions or through dispersion forces.
  • Non-limiting examples of these solvents include toluene, xylene, n-heptane, octane, isooctane, cyclohexane, pentane and 1 ,4-dioxane.
  • aprotic solvent means any molecular solvent which cannot donate H + .
  • aprotic solvents that may be used for the present invention include, but are not limited to: tetrahydrofuran (THF), 2-methyl THF, toluene, methyl cyclohexane, acetonitrile, methyl ethyl ketone (MEK), and methyl isobutyl ketone (MIBK).
  • antisolvent refers to a solvent in which the compound is not fully soluble. Suitable antisolvents for the purification process of rivaroxaban include alcohols, ketones, ethers, esters, hydrocarbons and any mixtures thereof.
  • alcohol refers to a hydrocarbon derivative in which one or more hydrogen atoms have been replaced by an -OH group.
  • Suitable alcohols for the present invention include C1-C6 linear, cyclic or branched alcohols and any mixtures thereof. It also includes commercially available alcohols.
  • amino protecting group refers to a protecting group for the amino moiety to hinder the reactivity of the amino group.
  • the amino group can be attached to an alkyl or aryl moiety or can be present as part of an amide or hydroxamide functional group.
  • suitable amino protecting groups can be found in, for example Greene's Protective Groups in Organic Synthesis.
  • Non-limiting examples of amino protecting groups are 9-fluorenylmethyl carbamate (Fmoc-NRR'), t-butyl carbamate (Boc-NRR'), benzyl carbamate (Z-NRR', Cbz-NRR'), acetamide, trifluoroacetamide, phthalimide, benzylamine (Bn-NRR'), triphenylmethylamine (Tr- NRR'), benzylideneamine and p-toluenesulfonamide (Ts-NRR').
  • the preferred amino protecting group is the phthalimide.
  • the term “one-pot process” refers to a process comprising simultaneously or successively adding all reactants into a reactor to have them react together, in which no separation and/or purification of the intermediate state is required before the final product is produced.
  • the term "inorganic base” as used herein refers to a substance that tends to accept a proton. It contains a metal cation and does not contain an organic moiety, as compared to an organic base, which is a substance that contains an organic moiety.
  • the inorganic bases preferred for the present invention are hydroxides of calcium, sodium, magnesium, potassium, lithium and caesium, and carbonates and bicarbonates of calcium, sodium, magnesium, potassium, lithium and caesium.
  • organic bases are carbonates and bicarbonates of sodium, potassium and lithium. Most preferred inorganic base is sodium carbonate.
  • organic amine refers to an organic (i.e., carbon-containing) compound containing at least one primary (i.e., -NH2) or secondary (i.e., -NH-). Examples of organic amines include, but are not limited to: methylamine, ethylamine, propylamine, isopropylamine, butylamine, isobutylamine, sec-butylamine, tert- butylamine, dimethylamine, diethylamine, dipropylamine, and the like.
  • aminoalcohol refers to an organic compound that contains both a primary amine functional group and a primary alcohol functional group.
  • the primary alcohol functional group can be C1-C8 lineal or branched alcohol.
  • Non- limiting examples of aminoalcohols are 2-aminoethanol, 3-aminopropanol, 4- aminobutanol.
  • phosgene equivalent refers to a compound able to replace phosgene (carbonyl dichloride) as a building block or reagent in organic syntheses, or able to specifically bring about the basic phosgene functions as a (cyclo)carbonylating, chlorocarbonylating, chlorinating or dihydrating agent. Examples of suitable phosgene equivalents can be found in, for example Phogenations- A Handbook. Cotarca L and Eckert H.32-43 (2003).
  • purification refers to the process wherein a purified drug substance can be obtained.
  • industrial purification refers to purifications, which can be carried out on an industrial scale such as solvent extraction, filtration, slurring, washing, phase separation, evaporation, centrifugation or crystallization.
  • solvent extraction refers to the process of separating components of a mixture by using a solvent which possesses greater affinity for one component, and may therefore separate said one component from at least a second component which is less miscible than said one component with said solvent.
  • filtration refers to the act of removing solid particles greater than a predetermined size from a feed comprising a mixture of solid particles and liquid.
  • the expression “filtrate” refers to the mixture less the solid particles removed by the filtration process. It will be appreciated that this mixture may contain solid particles smaller than the predetermined particle size.
  • filter cake refers to residual solid material remaining on a feed side of a filtration element.
  • cleaning refers to any process which employs a solvent to wash or disperse a crude product.
  • washing refers to the process of purifying a solid mass (e.g., crystals) by passing a liquid over and/or through the solid mass, as to remove soluble matter.
  • the process includes passing a solvent, such as distilled water, over and/or through a precipitate obtained from filtering, decanting, or a combination thereof.
  • a solvent such as distilled water
  • washing includes contacting solids with solvent or solvent mixture, vigorously stirring (e.g., for two hours), and filtering.
  • the solvent can be water, can be an aqueous solvent system, or can be an organic solvent system.
  • the washing can be carried out with the solvent having any suitable temperature.
  • the washing can be carried out with the solvent having a temperature between about 0 °C and about 100 °C.
  • phase separation refers to a solution or mixture having at least two physically distinct regions.
  • evaporation refers to the change in state of solvent from liquid to gas and removal of that gas from the reactor. Generally gas is removed by vacuum applied across the membrane.
  • solvents may be evaporated during the synthetic route disclosed herein. As known to those of skill in the art, each solvent may have a different evaporation time and/or temperature.
  • crystallization refers to any method known to a person skilled in the art such as crystallization from single solvent or combination of solvents by dissolving the compound optionally at elevated temperature and precipitating the compound by cooling the solution or removing solvent from the solution or both. It further includes methods such as solvent antisolvent or precipitation.
  • pure rivaroxaban refers to rivaroxaban of a purity obtained by HPLC of at least 98 % (w/w), preferably of at least 99% (w/w), most preferably of at least 99.5% (w/w).
  • Dx means that x% of the particles in a composition (based on volume) have a diameter below a specified D value.
  • a D50 of 400 ⁇ means that 50% of the particles, by volume, have a diameter below 400 ⁇ .
  • the first aspect of the invention relates to a process for the manufacturing of rivaroxaban or a pharmaceutically acceptable salt thereof, wherein the process comprises at least the following steps: i) obtaining an acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III), wherein the acid used to form the acid addition salt is an organic acid; ii) reacting the acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III) obtained in step (i) with the suitable reagents to obtain rivaroxaban or a salt thereof.
  • Scheme 3 depicts obtaining compound (III) from compound (II), and obtaining rivaroxaban from compound (III), wherein P is an amino protecting group and HA is an organic acid as previously defined.
  • Scheme 4 depicts a preferred embodiment of the process as herein disclosed.
  • the acid addition salt of 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3- yl]phenyl ⁇ morpholin-3-one (III) may be obtained by the deprotection of the amino protected precursor (compound II) in the presence of at least one suitable amino deprotecting agent followed by addition of an organic acid.
  • the amino protecting group P is phthalimide and the amino deprotecting agent is selected from the group consisting of organic amines, ammonia, aminoalcohols, hydrazine, H 2 , nucleophiles, and mixtures thereof.
  • the amino deprotecting agent is an organic amine, ammonia or mixtures thereof, more preferably the amino deprotecting agent is methylamine.
  • the deprotection of compound II is typically carried out in the presence of at least one organic solvent or a mixture of organic solvents, preferably a polar organic solvent or a mixture of polar organic solvents, more preferably alcohol or mixtures of alcohols, even more preferably the deprotection is carried out in ethanol, methanol or mixtures thereof.
  • the reaction mixture prepared in this step is normally heated to the reflux temperature of the solvent and stirred until the deprotection of compound II is completed.
  • the reaction may be carried out in one-pot, so, once the deprotection of compound II is completed, an organic acid, as previously defined, is added over the reaction mixture in order to generate compound III.
  • the organic acid can be added in a solid form, or as a dispersion or as a solution.
  • the reaction mixture can be at a temperature between 20 °C up to the reflux temperature of the solvent.
  • the organic acid is selected from oxalic acid, including oxalic acid dihydrate, fumaric acid, citric acid, including citric acid monohydrate, acetic acid, lactic acid, malic acid, malonic acid, maleic acid, tartaric acid, and formic acid.
  • another further advantage is that they are commercially available.
  • the organic acid is oxalic acid, including oxalic acid dihydrate, malonic acid or maleic acid, which allow obtaining acid addition salts of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3- yl]phenyl ⁇ morpholin-3-one with a HPLC purity of at least 98.4%.
  • the selected organic acid is the same as the one forming the acid addition salt. For example, if the desired addition salt is the malonate, the acid used to obtain it is malonic acid.
  • the organic acid is added in a solution of an organic solvent or mixtures of organic solvents.
  • the organic solvent is alcohol or mixtures of alcohols, selected from methanol, ethanol, propanol and butanol.
  • the most preferred alcohols are methanol, ethanol or mixtures thereof.
  • an alcoholic solution of the organic acid is added dropwise until pH between 1 and 6 is reached, preferably between 1.5 and 5, and more preferably between 1 .5 and 4, leading to the precipitation of the acid addition salt.
  • the organic acid addition can be carried out from about 20 °C up to the reflux temperature of the organic solvent of the deprotection step.
  • the deprotection and the addition of the organic acid are carried out in one-pot.
  • the molar ratio of compound Ikamino deprotecting agen organic acid is from 1 :3:3.5 to 1 :5.5:6.
  • step (i) in order to increase the purity of the final crude of rivaroxaban, between step (i) and step (ii) the process may comprise a further step (i').
  • step (i') the acid addition salt of 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one obtained in the previous steps is purified.
  • step (ii) the acid addition salt (III) is usually mixed with at least one equivalent of an inorganic base, as already defined, in a polar solvent.
  • the reaction mass should be kept at a temperature range between -5 and 15 °C, preferably between 0 and 10 °C.
  • Suitable inorganic bases are selected from hydroxides of calcium, sodium, magnesium, potassium, lithium and caesium, and carbonates and bicarbonates of calcium, sodium, magnesium, potassium, lithium and caesium.
  • Suitable polar solvents are, but not limited, ketones such as acetone, methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK); ethers such as tetrahydrofuran (THF), dioxane, diisopropyl ether or methyl tert-butyl ether; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol, isobutanol, sec-butanol or tert-butanol; water or mixtures thereof.
  • ketones such as acetone, methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK)
  • ethers such as tetrahydrofuran (THF), dioxane, diisopropyl ether or methyl tert-butyl ether
  • alcohols such as methanol, ethanol, is
  • the solvent is selected from ketones, ethers, water and mixtures thereof and the inorganic base is selected from carbonates and bicarbonates of sodium, potassium and lithium. More preferably, the solvent is an acetone/water mixture and the inorganic base is sodium carbonate.
  • suitable reagents to obtain rivaroxaban such as 5-chlorothiophene-2-carbonyl halide is added to the above reaction mixture and stirred, while the temperature is maintained in order to yield rivaroxaban.
  • a suitable reagent is 5- chlorothiophene-2-carbonyl chloride.
  • the molar ratio of the acid addition salt (III) to a suitable reagent such as 5- chlorothiophene-2-carbonyl halide may be from 1 :1 to 1 :3, preferably about 1 :1.5.
  • the reaction mixture is preferably heated to about 50 to 55 °C and further stirred.
  • the resulted crude rivaroxaban may be filtered off and washed with the reaction solvents, when still hot or at room temperature.
  • Suitable reagents such as 5-chlorothiophene-2-carbonyl halide may be prepared by mixing 5-chloro-2-thiophenecarboxylic acid with a thionyl halide, preferably thionyl chloride, and an organic solvent or mixtures thereof, preferably N,N- dimethylformamide (DMF), THF, acetone, toluene or mixtures thereof. Afterwards, the reaction mass may be heated to reflux temperature and part of the organic solvent can be distilled out in vacuum at 30-70 °C in order to remove the excess of thionyl chloride.
  • a thionyl halide preferably thionyl chloride
  • organic solvent or mixtures thereof preferably N,N- dimethylformamide (DMF), THF, acetone, toluene or mixtures thereof.
  • the 5-chlorothiophene-2-carbonyl chloride is added as a solution in an organic solvent, preferably toluene.
  • the molar ratio of the acid addition salt (III) to 5-chlorothiophene-2-carbonyl chloride is from 1 :1 to 1 :3, preferably about 1 :1 .5.
  • the reaction mixture is preferably heated from about 50 to 55 °C and further stirred.
  • the resulted crude rivaroxaban may be filtered off and washed with the reaction solvents, when still hot or at room temperature.
  • the 5- chlorothiophene-2-carbonyl chloride solution may be prepared by mixing 5-chloro-2- thiophenecarboxylic acid with a thionyl chloride, and an organic solvent or mixtures thereof, preferably DMF, THF, acetone, toluene or mixtures thereof. Afterwards, the reaction mass is heated to reflux temperature and part of the toluene distilled out in vacuum at 30-70 °C in order to remove the excess of thionyl chloride.
  • the second aspect of the invention relates to novel acid addition salts of general formula III:
  • HA is an organic acid, as already defined, which can be used as intermediates in the preparation process of rivaroxaban.
  • organic acid addition salts affords the manufacturing of rivaroxaban or salts thereof in high purity and high yields by a process that is more environmentally friendly and can be easily applied at industrial scale.
  • These acid addition salts of general formula III are also obtained in high purity and yield and can be easily isolated and purified by using standard industrial methods, avoiding the use of impractical column chromatography, which is a clear advantage, as previously explained.
  • the organic acid HA includes, high purity commercially available monoprotic, diprotic and triprotic acids, as already defined.
  • the organic acid is oxalic acid, including oxalic acid dihydrate, fumaric acid, citric acid, including citric acid monohydrate, acetic acid, lactic acid, malic acid, maleic acid, malonic acid, tartaric acid or formic acid.
  • the organic acid is oxalic acid, including oxalic acid dihydrate, citric acid, including citric acid monohydrate, acetic acid, lactic acid, malic acid, maleic acid or malonic acid.
  • the third aspect of the invention relates to the process for the preparation of the novel acid addition salts of general formula III, wherein HA is an organic acid, as already defined.
  • the acid addition salts of 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III) may be obtained by the deprotection of the amino protected precursor (compound II) in the presence of at least one suitable amino deprotecting agent followed by addition of an organic acid.
  • the amino protecting group P is phthalimide and the amino deprotecting agent is selected from the group consisting of organic amines, ammonia, aminoalcohols, hydrazine, H 2 , nucleophiles, and mixtures thereof.
  • the amino deprotecting agent is selected from the group consisting of organic amines, ammonia, aminoalcohols, hydrazine, H 2 , nucleophiles, and mixtures thereof.
  • the amino deprotecting agent is an organic amine, ammonia or mixtures thereof, more preferably the amino deprotecting agent is methylamine.
  • the deprotection of compound II is typically carried out in the presence of at least one organic solvent or a mixture of organic solvents, preferably a polar organic solvent or a mixture of polar organic solvents, more preferably alcohol or mixtures of alcohols, even more preferably the deprotection is carried out in ethanol, methanol or mixtures thereof.
  • the reaction mixture prepared in this step is normally heated to the reflux temperature of the solvent and stirred until the deprotection of compound II is completed.
  • the reaction may be carried out in one-pot, so, once the deprotection of compound II is completed, an organic acid, as previously defined, is added over the reaction mixture in order to generate compound III.
  • the organic acid can be added in a solid form, or as a dispersion or as a solution.
  • the reaction mixture can be at a temperature between 20 °C up to the reflux temperature of the solvent.
  • the organic acid is selected from oxalic acid, including oxalic acid dihydrate, citric acid, including citric acid monohydrate, acetic acid, lactic acid, malic acid, fumaric acid, malonic acid, maleic acid, tartaric acid, and formic acid.
  • oxalic acid including oxalic acid dihydrate
  • citric acid including citric acid monohydrate
  • acetic acid lactic acid
  • malic acid fumaric acid
  • malonic acid maleic acid, tartaric acid
  • formic acid formic acid.
  • another further advantage is that they are commercially available.
  • the organic acid is oxalic acid, including oxalic acid dihydrate, malonic acid or maleic acid, which allow obtaining acid addition salts of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3- one with a HPLC purity of at least 98.4%.
  • the selected organic acid is the same as the one forming the acid addition salt. For example, if the desired addition salt is the malonate, the acid used to obtain it is malonic acid.
  • the organic acid is added in a solution of an organic solvent or mixtures of organic solvents.
  • the organic solvent is alcohol or mixtures of alcohols, selected from methanol, ethanol, propanol and butanol.
  • the most preferred alcohols are methanol, ethanol or mixtures thereof.
  • an alcoholic solution of the organic acid is added dropwise until pH between 1 and 6 is reached, preferably between 1 .5 and 5, and more preferably between 1 .5 and 4, leading to the precipitation of the acid addition salt.
  • the organic acid addition can be carried out from about 20 °C up to the reflux temperature of the organic solvent of the deprotection step.
  • the deprotection and the addition of the organic acid are carried out in one-pot.
  • the molar ratio of compound Ikamino deprotecting agen organic acid is from 1 :3:3.5 to 1 :5.5:6.
  • the acid addition salt of 4- ⁇ 4-[(5S))-5-(aminomethyl)-2- oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III) obtained is isolated and therefore purified by standard industrial purification methods.
  • novel salts of 4- ⁇ 4-[(5S)-5-(aminomethyl)-2-oxo-1 ,3-oxazolidin-3- yl]phenyl ⁇ morpholin-3-one (III) having good yield and high HPLC purity are obtained.
  • the HPLC purity is in most of the cases is higher than 95%.
  • 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3- yl]phenyl ⁇ morpholin-3-one oxalate 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one citrate
  • 4- ⁇ 4-[(5S))-5-(aminomethyl)-2- oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one lactate 4- ⁇ 4-[(5S))-5-
  • 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3- yl]phenyl ⁇ morpholin-3-one oxalate, 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one malonate or 4- ⁇ 4-[(5S))-5-(aminomethyl)-2- oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one maleate are obtained.
  • Such salts are preferred since they can be obtained with a HPLC purity higher than 98.40%.
  • the acid addition salt obtained is in a solid form, preferably in a crystalline form.
  • the amino protected precursor (compound II), wherein P is phthalimide (2-( ⁇ (5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1 ,3-oxazolidin-5- yl ⁇ methyl)-1 H-isoindole-1 ,3(2H)-dione), is used for the preparation of novel acid addition salts of general formula III.
  • the 2-( ⁇ (5S)-2-oxo-3-[4-(3-oxo-4- morpholinyl)phenyl]-1 ,3-oxazolidin-5-yl ⁇ methyl)-1 H-isoindole-1 ,3(2H)-dione is prepared by cyclization of 2-((2R)-2-hydroxy-3- ⁇ [4-(3-oxo-4- morpholinyl)phenyl]amino ⁇ propyl-1 H-isoindole-1 ,3(2H)-dione in the presence of phosgene or phosgene equivalents, preferably ⁇ , ⁇ -carbonyldiimidazole (CDI) in an aprotic solvent, as already defined, and without the need of using a catalyst.
  • phosgene or phosgene equivalents preferably ⁇ , ⁇ -carbonyldiimidazole (CDI) in an aprotic solvent, as already defined, and without the need of
  • the preferred aprotic solvent is selected from tetrahydrofuran (THF), 2-methyl THF, acetonitrile, methyl ethyl ketone (MEK), and methyl isobutyl ketone (MIBK). More preferably, the aprotic solvent is tetrahydrofuran, acetonitrile or MIBK.
  • the 2-((2R)-2-hydroxy-3- ⁇ [4-(3-oxo-4-morpholinyl)phenyl]amino ⁇ propyl- 1 H-isoindole-1 ,3(2H)-dione is prepared by reacting 2-[(2S)-2-oxiranylmethyl]-1 H- isoindole-1 ,3(2H)-dione and 4-(4-aminophenyl)-3-morpholinone, using an alcohol, water or mixtures thereof, as a solvent.
  • the preferred solvent is ethanol.
  • the fourth aspect of the invention relates to the use of the acid addition salt of the second aspect, for the preparation of rivaroxaban and pharmaceutically acceptable salts thereof and for the preparation of a pharmaceutical composition comprising rivaroxaban or a pharmaceutically acceptable salt thereof.
  • An additional aspect of the invention relates to the purification of crude rivaroxaban, preferably the crude rivaroxaban obtained by the process as herein disclosed.
  • rivaroxaban is purified by means of industrial purification techniques such as solvent extraction, filtration, slurring, washing, phase separation, evaporation, centrifugation or crystallization.
  • the process comprises the following steps: a) heating the mixture of crude rivaroxaban with an organic solvent, wherein the solvent is selected from acetic acid, formic acid, DMF, aqueous mixtures thereof and mixtures thereof to a temperature higher than 50 °C, preferably until a clear solution is obtained; b) obtaining pure rivaroxaban by decreasing to a temperature between 0-30 °C, preferably between 20-30 °C.
  • the obtained solid is finally filtered off, and, if necessary, washed and dried.
  • the preferred organic solvents are formic acid and aqueous mixtures thereof.
  • the preferred ratio of crude rivaroxaban to the organic solvent is between 1 :5 and 1 :20.
  • the ratio herein described is mg of crude rivaroxaban to ml of the organic solvent.
  • the step (a) is carried out at the reflux temperature of the mixture.
  • the pure rivaroxaban of step (b) is obtained in crystalline form.
  • the mixture of step (a) may be obtained by mixing crude rivaroxaban with the organic solvent.
  • the purification process comprises the following steps: a) heating a mixture comprising crude rivaroxaban with at least two organic solvents, wherein one first solvent is selected from acetic acid, formic acid, DMF, aqueous mixtures thereof and mixtures thereof, preferably formic acid and aqueous mixtures thereof; and one second solvent is selected from acetone, acetonitrile, MEK, MIBK and mixtures thereof, preferably acetone, MEK, MIBK and mixtures thereof, to a temperature higher than 50 °C, preferably until a clear solution is obtained; b) obtaining pure rivaroxaban by decreasing the temperature of the mixture obtained in step (a) to a temperature between 0-30 °C, preferably between 20-30 °C.
  • the obtained solid is finally filtered off, and, if necessary, washed and dried.
  • the preferred first solvents are formic acid and aqueous mixtures thereof.
  • the preferred second solvents are acetone, MEK, MIBK and mixtures thereof.
  • the preferred ratio of crude rivaroxaban to the first organic solvent is between 1 :2 and 1 :20.
  • the preferred ratio of crude rivaroxaban to the second organic solvent is between 1 :2 and 1 :20.
  • the ratio herein described is mg of crude rivaroxaban to ml of the first organic solvent or the second organic solvent.
  • the step (a) is carried out at the reflux temperature of the mixture.
  • the pure rivaroxaban of step (b) is obtained in crystalline form.
  • the mixture comprising crude rivaroxaban with at least two organic solvents may be obtained of different manners. Preferably, it is obtained by mixing crude rivaroxaban with the two organic solvents of step (a). In that case, the crude rivaroxaban may be added to a mixture formed by the two organic solvents.
  • the crude rivaroxaban is mixed with one of the organic solvents, secondly such mixture is heated to a temperature higher than 50 °C (e.g. for about 1 hour), and finally the other organic solvent is added.
  • the process comprises the following steps: a) heating a mixture of crude rivaroxaban with an organic solvent or a mixture of organic solvents selected from acetic acid, formic acid, DMF, aqueous mixtures thereof and mixtures thereof to a temperature higher than 50 °C, preferably until a clear solution is obtained; b) decreasing the temperature to a temperature between 0-30 °C, preferably between 20-30 °C; c) obtaining a suspension of pure rivaroxaban by adding an antisolvent to the rivaroxaban mixture obtained in step (b); d) optionally stirring the rivaroxaban mixture obtained in step (c); e) decreasing the temperature of the rivaroxaban suspension at a temperature from -5 °C to 10 °C; f) optionally stirring the rivaroxaban mixture obtained; g) and isolating pure rivaroxaban, preferably by filtering off, and
  • the preferred antisolvents of step (c) are selected from acetone, MEK, MIBK, methyl cyclohexane, methanol, ethanol, ethyl acetate, acetonitrile, methyl tertiary butyl ether (MTBE), 2-methyl THF, water, aqueous mixtures thereof, or mixtures thereof. Even more preferred the antisolvent is acetone, MEK, MIBK, acetonitrile, water, or mixtures thereof.
  • the preferred ratio of crude rivaroxaban, organic solvent and antisolvent is between 1 :5:8 and 1 :10:22, respectively (crude rivarobaxan in mg, organic solvent in ml and antisolvent in ml)
  • the step (a) is carried out at the reflux temperature of the mixture.
  • the pure rivaroxaban of step (b) is obtained in crystalline form.
  • the mixture of step (a) may be obtained by mixing crude rivaroxaban with the organic solvent or the mixture of organic solvents.
  • Rivaroxaban as prepared and isolated by a process according to the present invention comprises polymorphic Modification I, having a melting point of around 232 °C as defined in US 7,157,456.
  • Rivaroxaban obtained according to the process of the present invention can be milled or micronised to obtain a D 50 and D 90 particle size of less than about 400 ⁇ , preferably less than about 200 ⁇ , more preferably less than about 150 ⁇ , still more preferably less than about 50 ⁇ and most preferably less than 15 ⁇ .
  • Particles of this size are obtained by conventional methods, based on the use of friction to reduce particle size. Such methods include milling, grinding in an air jet mill, hammer and screen mill, fine impact mill, ball mill or vibrator mill. Reduction in particle size may also take place as a result of collision and impact.
  • Rivaroxaban obtained according to the process of the present invention acts in particular as anticoagulant by means of selective inhibition of the blood coagulation factor Xa, and can be therefore preferably be employed in medicaments for the treatment and/or prevention of thromboembolic disorders.
  • thromboembolic disorders include, in particular serious disorders such as myocardial infarct, angina pectoris (including unstable angina), reocclusions and restenoses after angioplasty or aortocoronary bypass, stroke, transitory ischemic attacks, peripheral arterial occlusion disorders, pulmonary embolisms, deep venous thrombosis or venous thromboembolism.
  • the fifth aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of rivaroxaban prepared according to the first aspect together with appropriate amount of pharmaceutically acceptable excipients or carriers.
  • Administration of said pharmaceutical composition is preferably carried out orally, lingually, sublingually, bucally, rectally, pulmonary, nasally, dermally, transdermally, conjunctivally, optically, parenterally (i.e. bypassing the intestinal tract, that is intravenously, intraarterially, intracardially, intracutaneously, subcutaneously, transdermally, intraperitoneally or intramuscularly) or as an implant or stent.
  • parenterally i.e. bypassing the intestinal tract, that is intravenously, intraarterially, intracardially, intracutaneously, subcutaneously, transdermally, intraperitoneally or intramuscularly
  • Particularly preferred are oral and parenteral administrations.
  • Particularly preferred is oral administration.
  • rivaroxaban is administered in amounts from approximately 0.001 to 10 mg/kg, preferably approximately 0.01 to 10 mg/kg, in particular approximately 0.1 to 8 mg/kg, of body weight to achieve effective results.
  • the dose of rivaroxaban is approximately 0.01 to 100 mg/kg, preferably approximately 0.01 to 20 mg/kg, in particular from about 0.1 to 10 mg/kg of body weight.
  • the pharmaceutical composition of the present invention may take the form of a dosage unit such as a tablet, capsule or a suppository.
  • a preferred pharmaceutical composition is a tablet.
  • the composition is a film-coated tablet.
  • a dosage unit of the present invention containing rivaroxaban and suitable for the treatment and/or prevention of "thromboembolic disorders", as defined above, may contain about 0.0005 to 500 mg of the rivaroxaban obtained according to the process of the invention.
  • a preferred dosage unit may contain 1-20 mg of rivaroxaban obtained according to the process of the present invention.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, powders, granules, and aqueous suspensions and solutions. These dosage forms are prepared according to techniques well-known in the art of pharmaceutical formulation. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavouring and/or colouring agents may be added.
  • the pharmaceutical compositions of this invention may further comprises one or more pharmacologically active ingredients.
  • rivaroxaban or a pharmaceutical composition as defined above, for the use in the treatment or prevention of "thromboembolic disorders", as previously defined.
  • the present invention provides a method of treatment or prevention of "thromboembolic disorders", as previously defined, the method comprising the administration, to a subject in need of such treatment or prevention, of rivaroxaban or a pharmaceutical composition as defined above.
  • the rivaroxaban or the pharmaceutical composition obtained according to the process described in the present invention is used for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.
  • VTE venous thromboembolism
  • the invention provides the use of rivaroxaban of the present invention for the preparation of a medicament for the treatment or prevention of "thromboembolic disorders", as previously defined.
  • Another aspect of the present invention relates to a process for the manufacturing of rivaroxaban or a pharmaceutically acceptable salt thereof, wherein the process comprises at least the following steps: i) obtaining an acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III), wherein the acid used to form the acid addition salt is an organic acid; ii) reacting the acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III) obtained in step (i) with the suitable reagents to obtain rivaroxaban or a salt thereof.
  • Another aspect of the present invention relates to a process for the manufacturing of rivaroxaban or a pharmaceutically acceptable salt thereof, wherein the process comprises at least the following steps: i) obtaining an acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III), wherein the acid used to form the acid addition salt is an organic acid; ii) reacting the acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III) obtained in step (i) with the suitable reagents to obtain rivaroxaban or a salt thereof; wherein the acid addition salt obtained in step (i) is isolated in a solid form, preferably in a crystalline form, before carrying step (ii).
  • Another aspect of the present invention relates to a process for the manufacturing of rivaroxaban or a pharmaceutically acceptable salt thereof, wherein the process comprises at least the following steps: i) obtaining an acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one, wherein the acid used to form the acid addition salt is an organic acid, with the proviso that the organic acid is not oxalic acid, fumaric acid, citric acid, maleic acid, tartaric acid, succinic acid, mandelic acid or benzoic acid; ii) reacting the acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one obtained in step (i) with the suitable reagents to obtain rivaroxaban
  • Another aspect of the present invention relates to a process for the manufacturing of rivaroxaban or a pharmaceutically acceptable salt thereof, wherein the process comprises at least the following steps: i) obtaining an acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one, wherein the acid used to form the acid addition salt is an organic acid selected from oxalic acid dihydrate, malonic acid, citric acid monohydrate, acetic acid, formic acid, trifluoroacetic acid, gluconic acid, lactic acid, malic acid, acetyl salicylic acid, adipic acid, pivalic acid, phenylacetic acid, p-methoxybenzoic acid, 4-pyridylcarboxylic acid, oleic acid, organosulfur compounds, embonic acid, gentisic acid, glucuronic acid, py
  • Another aspect of the present invention relates to a process for the manufacturing of rivaroxaban or a pharmaceutically acceptable salt thereof, wherein the process comprises at least the following steps: i) obtaining an acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III), wherein the acid used to form the acid addition salt is an organic acid; ii) reacting the acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III) obtained in step (i) with the suitable reagents to obtain rivaroxaban or a salt thereof, wherein one of the suitable reagents is an inorganic base.
  • the invention relates to any of the processes defined above, wherein the acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine- 3-yl]phenyl ⁇ morpholin-3-one obtained in step (i) is isolated in a solid form, preferably in a crystalline form, before carrying step (ii).
  • the invention relates to any of the processes defined above, wherein one of the suitable reagents of step (ii) is an inorganic base, preferably wherein the inorganic base is selected from carbonates and bicarbonates of sodium potassium and lithium, and more preferably wherein the inorganic base is selected from sodium carbonate.
  • the invention relates to any of the processes defined above, wherein the organic acid is a R 2 COOH compound, or to mixtures of R 2 COOH compounds, wherein R 2 is a linear or branched, saturated alkyl, unsaturated alkyl, an aryl or a heteroaryl, said R 2 group being optionally substituted by one or more halogen, hydroxyl, alkoxyl, carboxyl, carboalkoxyl, aryl or heteraryl groups, and said acid R 2 COOH having between 1 and 18 carbon atoms.
  • R 2 is a linear or branched, saturated alkyl, unsaturated alkyl, an aryl or a heteroaryl, said R 2 group being optionally substituted by one or more halogen, hydroxyl, alkoxyl, carboxyl, carboalkoxyl, aryl or heteraryl groups, and said acid R 2 COOH having between 1 and 18 carbon atoms.
  • the invention relates to any of the processes defined above, wherein the organic acid is oxalic acid, including oxalic acid dihydrate, citric acid, including citric acid monohydrate, acetic acid, lactic acid, malic acid, fumaric acid, malonic acid, tartaric acid, formic acid, maleic acid or mixtures thereof, preferably oxalic acid, including oxalic acid dihydrate, citric acid, including citric acid monohydrate, acetic acid, lactic acid, malic acid, maleic acid or malonic acid, more preferably the organic acid is oxalic acid dihydrate, citric acid monohydrate, acetic acid, lactic acid, malic acid, malonic acid or formic acid, and even more preferably the organic acid is oxalic acid dihydrate, malonic acid or maleic acid.
  • the organic acid is oxalic acid, including oxalic acid dihydrate, citric acid, including citric acid monohydrate, acetic acid, lactic acid, malic acid, malonic
  • the invention relates to any of the processes defined above, wherein an acid addition salt consisting essentially of an acid addition salt of a 4- ⁇ 4- [(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III) and an organic acid is obtained in the step (i).
  • the invention relates to any of the processes defined above, wherein the acid addition salt of the 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one (III) is obtained by reacting the 4- ⁇ 4-[(5S))- 5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one with a suitable acid or a suitable acid precursor to obtain the acid addition salt.
  • the invention relates to any of the processes defined above, wherein the suitable acid is the same acid as the one forming the acid addition salt.
  • the invention relates to any of the processes defined above, wherein the organic acid is added to a solution formed by the 4- ⁇ 4-[(5S))-5- (aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one and a first solvent.
  • the first solvent is an organic solvent or a mixture of organic solvents, wherein the first solvent comprises at least an alcohol or mixtures of alcohols, preferably methanol, ethanol or mixtures thereof.
  • the first solvent consists essentially of at least an alcohol, or mixtures of alcohols, preferably, the first solvent is an alcohol.
  • the first solvent consists essentially of an alcohol, or mixtures of alcohols, preferably, the first solvent is an alcohol.
  • the alcohol is selected from the group consisting of methanol, ethanol, propanol, butanol and mixtures thereof, preferably methanol, ethanol or mixtures thereof.
  • the invention relates to any of the processes defined above, wherein the organic acid is added in a solid form, in dispersion or in a solution of a second solvent.
  • the invention relates to any of the processes defined above, wherein the organic acid is added in a solution of a second solvent, and the second solvent comprises, preferably consists essentially of, an organic solvent or mixtures of organic solvents
  • the second solvent is an alcohol, or a mixture of alcohols.
  • the alcohol is methanol, ethanol, propanol, butanol and mixtures thereof, preferably methanol, ethanol or mixtures thereof.
  • the invention relates to any of the processes defined above, wherein during the addition of the organic acid the temperature of the solution comprising the 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3- yl]phenyl ⁇ morpholin-3-one is from 20 °C to reflux temperature of the first solvent.
  • the invention relates to any of the processes defined above, wherein the organic acid is added until a pH between 1 and 6 is reached, preferably between 1 .5 and 5, and more preferably between 1 .5 and 4.
  • the invention relates to any of the processes defined above, wherein the 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3- yl]phenyl ⁇ morpholin-3-one is obtained by the deprotection of an amino protected precursor.
  • the invention relates to any of the processes defined above, wherein the amine is protected by an amino protecting group and the amino protecting group is selected from the group consisting of 9-fluorenylmethyl carbamate t-butyl carbamate, benzyl carbamate, acetamide, trifluoroacetamide, phthalimide, benzylamine, triphenylmethylamine, benzylideneamine and p-toluenesulfonamide, preferably phthalimide.
  • the invention relates any of the processes defined above, wherein the amino protected precursor is deprotected in the presence of at least one suitable amino deprotecting agent.
  • the invention relates to any of the processes defined above, wherein the amino protecting group is phthalimide and the deprotecting agent is selected from the group consisting of organic amines, ammonia, hydrazine, H 2 , nucleophiles, and mixtures thereof, preferably the deprotecting agent is an organic amine, ammonia or mixtures thereof, more preferably the deprotecting agent is methylamine.
  • the invention relates to any of the processes defined above, wherein the deprotection is carried out in at least one organic solvent, preferably a polar organic solvent, more preferably alcohol.
  • the invention relates to any of the processes defined above, wherein the deprotection is carried out in the presence of at least one organic solvent or a mixture of organic solvents, preferably a polar organic solvent or a mixture of polar organic solvents, more preferably alcohol or mixtures thereof, the most preferably ethanol, methanol or mixtures thereof.
  • at least one organic solvent or a mixture of organic solvents preferably a polar organic solvent or a mixture of polar organic solvents, more preferably alcohol or mixtures thereof, the most preferably ethanol, methanol or mixtures thereof.
  • the invention relates to any of the processes defined above, wherein the amino protecting group is phthalimide and the deprotection is carried out in the presence of a polar organic solvent, preferably alcohol, more preferably ethanol, methanol or mixtures thereof.
  • a polar organic solvent preferably alcohol, more preferably ethanol, methanol or mixtures thereof.
  • the invention relates to any of the processes defined above, wherein the deprotection is carried out in the presence of ethanol, methanol or mixtures thereof as a solvent.
  • the invention relates to any of the processes defined above, wherein the deprotection and the step (i) is carried out in one-pot. In another embodiment, the invention relates to any of the processes defined above, which further comprises a step (i'), wherein in such step (i') the salt obtained in the previous step (i) is purified before step (ii).
  • the invention relates to any of the processes defined above, wherein the step (ii) comprises reacting the acid addition salt with a 5- chlorothiophene-2-carbonyl halide, preferably 5-chlorothiophene-2-carbonyl chloride.
  • the invention relates to any of the processes defined above, wherein the step (ii) comprises reacting the acid addition salt with a 5- chlorothiophene-2-carbonyl halide, preferably 5-chlorothiophene-2-carbonyl chloride, and at least one base, preferably at least about one equivalent of a base.
  • a 5- chlorothiophene-2-carbonyl halide preferably 5-chlorothiophene-2-carbonyl chloride
  • the invention relates to any of the processes defined above, wherein the step (ii) comprises reacting the acid addition salt with a 5- chlorothiophene-2-carbonyl halide, preferably 5-chlorothiophene-2-carbonyl chloride, and at least one inorganic base, preferably at least about one equivalent of an inorganic base.
  • the step (ii) is carried out in a polar solvent, preferably a ketone, an ether, an alcohol, water or mixtures thereof.
  • the invention relates to any of the processes defined above, wherein the step (ii) comprises reacting the acid addition salt with a 5- chlorothiophene-2-carbonyl halide, preferably 5-chlorothiophene-2-carbonyl chloride; and at least one inorganic base, preferably at least about one equivalent of an inorganic base, wherein the inorganic base is selected from hydroxides of calcium, sodium, magnesium, potassium, lithium and caesium, and carbonates and bicarbonates of calcium, sodium, magnesium, potassium, lithium and caesium, preferably, the inorganic base is selected from carbonates and bicarbonates of sodium, potassium and lithium, and even more preferably, the inorganic base is sodium carbonate; and wherein the process is carried out in a polar solvent, preferably a ketone, an ether, an alcohol, water or mixtures thereof, more preferably, the solvent is a ketone/water mixture, and most preferably, the solvent is an acetone/water mixture.
  • a polar solvent
  • Another aspect of the present invention relates to a process for the manufacturing of rivaroxaban or a pharmaceutically acceptable salt thereof, wherein the process comprises at least the following steps: i) obtaining an acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one, wherein the acid used to form the acid addition salt is an inorganic acid with the proviso that the inorganic acid is not hydrochloric acid; ii) reacting the acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one obtained in step (i) with the suitable reagents to obtain rivaroxaban or a salt thereof, wherein the acid used to form the acid addition salt is an inorganic acid with the proviso that the in
  • Another aspect of the present invention relates to a process for preparing pure rivaroxaban, wherein the process comprises the following steps: a) heating the mixture of crude rivaroxaban with an organic solvent, wherein the solvent is selected from acetic acid, formic acid, DMF, aqueous mixtures thereof and mixtures thereof to a temperature higher than 50 °C, preferably until a clear solution is obtained; b) obtaining pure rivaroxaban by decreasing the temperature to a temperature between 0-30 °C, preferably between 20-30 °C.
  • the invention relates to the process as defined above, wherein the ratio of crude rivaroxaban to the organic solvent is preferably between 1 :5 and 1 :20.
  • the ratio herein described is mg of crude rivaroxaban to ml of the organic solvent.
  • the invention relates to the process as defined above, wherein the step (a) is carried out at the reflux temperature of the mixture. In another embodiment the invention relates to the process as defined above, wherein the pure rivaroxaban of step (b) is obtained in crystalline form.
  • the invention relates to the process as defined above, wherein the mixture of step (a) is obtained by mixing crude rivaroxaban with the organic solvent.
  • Another aspect of the present invention relates to a process for preparing pure rivaroxaban, wherein the process comprises the following steps: a) heating a mixture comprising crude rivaroxaban with at least two organic solvents, wherein one first solvent is selected from acetic acid, formic acid, DMF, aqueous mixtures thereof and mixtures thereof, preferably formic acid and aqueous mixtures thereof; and one second solvent is selected from acetone, acetonitrile, MEK, MIBK and mixtures thereof, preferably acetone, MEK, MIBK and mixtures thereof, to a temperature higher than 50 °C; b) obtaining pure rivaroxaban by decreasing the temperature of the mixture obtained in step (a) to a temperature between 0-30 °C, preferably between 20-30 °C.
  • the invention relates to the process as defined above, wherein the ratio of crude rivaroxaban to the first organic solvent is between 1 :2 and 1 :20 and the ratio of crude rivaroxaban to the second organic solvent is between 1 :2 and 1 :20.
  • the ratio herein described is mg of crude rivaroxaban to ml of the first organic solvent or the second organic solvent.
  • the invention relates to the process as defined above, wherein the step (a) is carried out at the reflux temperature of the mixture. In another embodiment the invention relates to the process as defined above, wherein the pure rivaroxaban of step (b) is obtained in crystalline form.
  • step (a) is obtained by mixing crude rivaroxaban with the two organic solvents of step (a).
  • the invention relates to the process as defined above, wherein the crude rivaroxaban is added to a mixture formed by the two organic solvents.
  • the invention relates to the process as defined above, wherein firstly the crude rivaroxaban is mixed with one of the organic solvents, secondly such mixture is heated to a temperature higher than 50 °C, and finally the other organic solvent is added.
  • Another aspect of the present invention relates to a process for preparing pure rivaroxaban, wherein the process comprises the following steps: a) heating a mixture of crude rivaroxaban with an organic solvent or a mixture of organic solvents selected from acetic acid, formic acid, DMF, aqueous mixtures thereof and mixtures thereof to a temperature higher than 50 °C; b) decreasing the temperature of the rivaroxaban mixture obtained to a temperature between 0-30 °C, preferably between 20-30 °C; c) obtaining a suspension pure rivaroxaban by adding an antisolvent to the rivaroxaban mixture obtained in step (b); d) optionally stirring the rivaroxaban mixture obtained in step (c); e) decreasing the temperature of the rivaroxaban suspension at a temperature from -5 °C to 10 °C; f) optionally stirring the rivaroxaban mixture obtained; g) and isolating pure rivaroxaban, preferably by
  • the invention relates to the process as defined above, wherein the antisolvent of step (c) is selected from acetone, MEK, MIBK, methyl cyclohexane, methanol, ethanol, ethyl acetate, acetonitrile, methyl tertiary butyl ether (MTBE), 2-methyl THF, water or mixtures thereof, preferably acetone, MEK, MIBK, acetonitrile, water, and mixtures thereof.
  • the antisolvent of step (c) is selected from acetone, MEK, MIBK, methyl cyclohexane, methanol, ethanol, ethyl acetate, acetonitrile, methyl tertiary butyl ether (MTBE), 2-methyl THF, water or mixtures thereof, preferably acetone, MEK, MIBK, acetonitrile, water, and mixtures thereof.
  • the invention relates to the process as defined above, wherein the ratio of crude rivaroxaban, organic solvent and antisolvent is between 1 :5:8 and 1 :10:22, respectively (crude rivarobaxan in mg, organic solvent in ml and antisolvent in ml)
  • the invention relates to the process as defined above, wherein the step (a) is carried out at the reflux temperature of the mixture. In another embodiment the invention relates to the process as defined above, wherein the pure rivaroxaban is obtained in crystalline form.
  • the invention relates to the process as defined above, wherein the mixture is obtained by mixing crude rivaroxaban with the organic solvent or the mixture of organic solvents.
  • Another aspect of the present invention relates to an acid addition salt of a 4- ⁇ 4- [(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one, wherein the acid used to form the acid addition salt is an organic acid.
  • Another aspect of the present invention relates to an acid addition salt of a 4- ⁇ 4- [(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one, wherein the acid used to form the acid addition salt is an organic acid, with the proviso that the organic acid is not oxalic acid, fumaric acid, citric acid, maleic acid, tartaric acid, succinic acid, mandelic acid or benzoic acid.
  • Another aspect of the present invention relates to an acid addition salt of a 4- ⁇ 4- [(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one, wherein the acid used to form the acid addition salt is an organic acid, selected from oxalic acid dihydrate, malonic acid, citric acid monohydrate, acetic acid, formic acid, trifluoroacetic acid, gluconic acid, lactic acid, malic acid, acetyl salicylic acid, adipic acid, pivalic acid, phenylacetic acid, p-methoxybenzoic acid, 4-pyridylcarboxylic acid, oleic acid, organosulfur compounds, embonic acid, gentisic acid, glucuronic acid, pyroglutamic acid, glycolic acid, aspartic acid, hippuric acid, glutaric acid, pimelic acid, palmitic acid and their mixtures.
  • the organic acid used to form the acid addition salt is oxalic acid dihydrate, malonic acid, citric acid monohydrate, acetic acid, formic acid, lactic acid, malic acid or mixtures thereof, more preferably oxalic acid dihydrate, malonic acid, citric acid monohydrate, acetic acid, formic acid, lactic acid or malic acid.
  • the most preferably organic acid is malonic acid or formic acid.
  • Another aspect of the present invention relates to an acid addition salt of a 4- ⁇ 4- [(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one, wherein the acid used to form the acid addition salt is an organic acid, preferably the acid addition salt is 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3- yl]phenyl ⁇ morpholin-3-one oxalate, 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one citrate, 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo- 1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one acetate, 4- ⁇ 4-[(
  • the invention relates to the acid addition salt, as defined above, which is selected from 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3- yl]phenyl ⁇ morpholin-3-one malonate and 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3- oxozoladine-3-yl]phenyl ⁇ morpholin-3-one formate.
  • the invention relates to the acid addition salt, according to any of the aspects defined above, wherein the organic acid addition salt is in a solid form, preferably in a crystalline form.
  • Another aspect of the present invention relates to an acid addition salt of a 4- ⁇ 4- [(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one, wherein the acid used to form the acid addition salt is an organic acid and the salt is in a solid form, preferably in a crystalline form.
  • Another aspect of the present invention relates to the use of an acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one, for the preparation of rivaroxaban and pharmaceutically acceptable salts thereof.
  • the invention relates to the use of an acid addition salt of a 4- ⁇ 4-[(5S))-5-(aminomethyl)-2-oxo-1 ,3-oxozoladine-3-yl]phenyl ⁇ morpholin-3-one as defined above, for the preparation of a pharmaceutical composition comprising rivaroxaban or a pharmaceutically acceptable salt thereof.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of rivaroxaban prepared according to any of the processes defined above together with appropriate amount of pharmaceutically acceptable excipients or carriers.
  • the invention relates to the pharmaceutical composition as defined above, further comprising one or more pharmacologically active ingredients.
  • the invention relates to the pharmaceutical composition defined above for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.
  • VTE venous thromboembolism
  • reaction mass was heated again to 65.0°C and 14.25 g (0.095 mol) of oxalic acid dihydrate in 50 mL of methanol were added dropwise within 30 min. Then, the reaction mass was heated to reflux for another 5 hours. After allowing cooling to 0-5 °C, the solid was filtered off and dried under vacuum at 50 °C.
  • the crude product was slurried in 125 mL of toluene and 16.5 mL of triethylamine were added to the reaction mass at 25 °C. Afterwards, 17.81 g (0.098 mol) of 5-chlorothiophene-2-carbonyl chloride in 100 mL of toluene were added dropwise and the reaction mass was stirred for 1 hour at 25 °C. At this stage, the reaction mass was heated at 50 °C for 1 hour and 75 ml of water was added at the same temperature. Finally, the resulting product was filtered off, washed with water and dried under vacuum at 50 °C.
  • the crude product was slurried in 125 mL of acetone and 16.5 mL of triethylamine were added to the reaction mass at 25 °C. Afterwards, 17.81 g (0.098 mol) of 5-chlorothiophene-2-carbonyl chloride in 100 mL of toluene were added dropwise and the reaction mass was stirred for 1 hour at 25 °C. At this stage, the reaction mass was heated at 50 °C for 1 hour and 75 mL of water was added at the same temperature. Finally, the resulting product was filtered off, washed with water and dried under vacuum at 50 °C.
  • Example 16 Purification of crude rivaroxaban.
  • Example 17 Purification of crude rivaroxaban.
  • Example 18 Purification of crude rivaroxaban.
  • Example 19 Purification of crude rivaroxaban.
  • Example 20 Purification of crude rivaroxaban.
  • Example 21 Purification of crude rivaroxaban.
  • Example 23 Purification of crude rivaroxaban.
  • Example 24 Purification of crude rivaroxaban.
  • Example 25 Purification of crude rivaroxaban.
  • Example 26 Purification of crude rivaroxaban.
  • Example 27 Purification of crude rivaroxaban.
  • Example 28 Purification of crude rivaroxaban.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé de production de rivaroxaban ou d'un sel pharmaceutiquement acceptable de celui-ci, le procédé consistant à obtenir un sel d'addition acide d'une 4-{4-[(5S))-5-(aminométhyl)-2-oxo-1,3-oxozoladine-3-yl]phényl}morpholin-3-one, et à faire réagir le sels d'addition acide avec les réactifs appropriés pour obtenir le rivaroxaban ou un sel de celui-ci.
PCT/EP2012/070034 2011-10-10 2012-10-10 Procédé de préparation d'inhibiteurs du facteur xa WO2013053739A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161545519P 2011-10-10 2011-10-10
US61/545,519 2011-10-10
EP11184532.7 2011-10-10
EP11184532 2011-10-10

Publications (1)

Publication Number Publication Date
WO2013053739A1 true WO2013053739A1 (fr) 2013-04-18

Family

ID=48081394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/070034 WO2013053739A1 (fr) 2011-10-10 2012-10-10 Procédé de préparation d'inhibiteurs du facteur xa

Country Status (1)

Country Link
WO (1) WO2013053739A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513115A (ja) * 2011-05-06 2014-05-29 エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ リバロキサバンの製法及び該方法において形成される中間体
CN104211693A (zh) * 2014-08-07 2014-12-17 成都百裕科技制药有限公司 一种利伐沙班新晶型及其制备方法与用途
CN104211694A (zh) * 2014-08-14 2014-12-17 广东东阳光药业有限公司 一种改进的制备Xa因子抑制剂的方法
WO2015104605A1 (fr) 2014-01-08 2015-07-16 Wockhardt Limited Procédé de préparation de rivaroxaban ou d'un sel pharmaceutiquement acceptable de ce dernier
CN104807934A (zh) * 2015-04-30 2015-07-29 成都百裕科技制药有限公司 异吲哚二酮类化合物的正相高效液相色谱检测方法
WO2015198259A1 (fr) * 2014-06-26 2015-12-30 Erregierre S.P.A. Procédé de synthèse de rivaroxaban et intermédiaire pour la production de celui-ci
CN105267169A (zh) * 2015-12-07 2016-01-27 石家庄康贺威药业有限公司 一种利伐沙班片剂及其制备方法
CN105440028A (zh) * 2015-12-07 2016-03-30 石家庄康贺威药业有限公司 一种利伐沙班化合物及其制备方法
CN106008490A (zh) * 2016-01-11 2016-10-12 南京生命能科技开发有限公司 一种利伐沙班的新晶体及其制备方法
EP3565552A4 (fr) * 2017-01-04 2020-07-08 Unichem Laboratories Ltd Procédé amélioré pour la préparation de rivaroxaban impliquant un nouvel intermédiaire
CN111675705A (zh) * 2020-08-11 2020-09-18 北京鑫开元医药科技有限公司 一种4-(4-氨基苯基)吗啉-3-酮衍生物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157456B2 (en) 1999-12-24 2007-01-02 Bayer Healthcare Ag Substituted oxazolidinones and their use in the field of blood coagulation
US7351823B2 (en) 2004-01-15 2008-04-01 Bayer Healthcare Ag Preparation process

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157456B2 (en) 1999-12-24 2007-01-02 Bayer Healthcare Ag Substituted oxazolidinones and their use in the field of blood coagulation
US7351823B2 (en) 2004-01-15 2008-04-01 Bayer Healthcare Ag Preparation process

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Crystalline forms of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one", IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 7 December 2009 (2009-12-07), XP013135806, ISSN: 1533-0001 *
COTARCA L.; ECKERT H.: "Phogenations- A Handbook", 2003, pages: 32 - 43
ICH GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS, Q7A, CURRENT STEP 4 VERSION, 10 November 2000 (2000-11-10)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513115A (ja) * 2011-05-06 2014-05-29 エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ リバロキサバンの製法及び該方法において形成される中間体
WO2015104605A1 (fr) 2014-01-08 2015-07-16 Wockhardt Limited Procédé de préparation de rivaroxaban ou d'un sel pharmaceutiquement acceptable de ce dernier
WO2015198259A1 (fr) * 2014-06-26 2015-12-30 Erregierre S.P.A. Procédé de synthèse de rivaroxaban et intermédiaire pour la production de celui-ci
CN104211693B (zh) * 2014-08-07 2017-02-22 成都百裕制药股份有限公司 一种利伐沙班晶型及其制备方法与用途
CN104211693A (zh) * 2014-08-07 2014-12-17 成都百裕科技制药有限公司 一种利伐沙班新晶型及其制备方法与用途
CN104211694A (zh) * 2014-08-14 2014-12-17 广东东阳光药业有限公司 一种改进的制备Xa因子抑制剂的方法
CN104807934A (zh) * 2015-04-30 2015-07-29 成都百裕科技制药有限公司 异吲哚二酮类化合物的正相高效液相色谱检测方法
CN105267169A (zh) * 2015-12-07 2016-01-27 石家庄康贺威药业有限公司 一种利伐沙班片剂及其制备方法
CN105440028A (zh) * 2015-12-07 2016-03-30 石家庄康贺威药业有限公司 一种利伐沙班化合物及其制备方法
CN106008490A (zh) * 2016-01-11 2016-10-12 南京生命能科技开发有限公司 一种利伐沙班的新晶体及其制备方法
CN106008490B (zh) * 2016-01-11 2019-01-04 南京生命能科技开发有限公司 一种利伐沙班的新晶体及其制备方法
EP3565552A4 (fr) * 2017-01-04 2020-07-08 Unichem Laboratories Ltd Procédé amélioré pour la préparation de rivaroxaban impliquant un nouvel intermédiaire
US11034683B2 (en) * 2017-01-04 2021-06-15 Unichem Laboratories Ltd Process for the preparation of rivaroxaban involving novel intermediate
US20210387979A1 (en) * 2017-01-04 2021-12-16 Unichem Laboratories Ltd Process for the preparation of rivaroxaban involving novel intermediate
US11891384B2 (en) 2017-01-04 2024-02-06 Unichem Laboratories Ltd Process for the preparation of Rivaroxaban involving novel intermediate
CN111675705A (zh) * 2020-08-11 2020-09-18 北京鑫开元医药科技有限公司 一种4-(4-氨基苯基)吗啉-3-酮衍生物的制备方法

Similar Documents

Publication Publication Date Title
WO2013053739A1 (fr) Procédé de préparation d'inhibiteurs du facteur xa
CA2730681C (fr) Intermediaire de fosaprepitant dimeglumine, fosaprepitant neutre et fosaprepitant dimeglumine amorphe et ses procedes de preparation
CA3149963A1 (fr) Inhibiteurs heterocycliques de la kinase rip1
JP2021517118A (ja) タファミジスを合成するための新たな経路及び新たな多形体
TW201629057A (zh) 新穎化合物αｖβ整聯蛋白拮抗劑
WO2015040640A2 (fr) Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
US9096574B2 (en) Polymorphs of perampanel
JP6592512B2 (ja) 三環式アトロプ異性体の化合物
WO2011158248A2 (fr) Procédé pour la préparation de posaconazole et forme polymorphique cristalline v de posaconazole
US20060241158A1 (en) Zolmitriptan crystal forms
WO2012156983A1 (fr) Procédés pour la préparation de 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phényl]-1,3-oxazolidin-5-yl}méthyl)-2-thiophènecarboxamide
US10144708B2 (en) Crystalline arylalkylamine compound and process for producing the same
WO2010092591A2 (fr) Nouveaux polymorphes cristallins de la 5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy]-3-(4-fluorophényl)-4-morpholinyl]méthyl]-1,2-dihydro-3h-1,2,4-triazol-3-one et leur procédé de préparation
WO2018109786A1 (fr) Nouveaux polymorphes et sels de dérivés de carbamoyle pyridone polycycliques
JPH10504820A (ja) Ｎ−置換されたフェノチアジン類の使用
JP5642766B2 (ja) アデフォビルジピボキシルの新規結晶形及びその製造方法
CN107739371B (zh) 一类四氢咔唑类小分子有机化合物及其在制备抗菌药物中的用途及其制备方法
JP6275644B2 (ja) Ｎ−［２−（｛２−［（２Ｓ）−２−シアノピロリジン−１−イル］−２−オキソエチル｝アミノ）−２−メチルプロピル］−２−メチルピラゾロ［１，５−ａ］ピリミジン−６−カルボキサミドの結晶
TWI399374B (zh) 新穎晶體形式及製備方法以及其醫藥組合物
WO2021093860A1 (fr) Composé bis-tricyclique substitué, composition pharmaceutique et utilisation de celui-ci
WO2012019862A1 (fr) Procédé pour fabriquer du linézolid
WO2015149270A1 (fr) Forme cristalline du semi-succinate de trélagliptine, sa méthode de préparation et sa composition pharmaceutique
JP2024516199A (ja) バルベナジンの合成方法
JPH0967347A (ja) 環状アミン誘導体及びそれを含有する医薬組成物
TW202402735A (zh) Ｎ－（吡咯啶－３－基或哌啶－４－基）乙醯胺衍生物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12772915

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12772915

Country of ref document: EP

Kind code of ref document: A1